Literature DB >> 31359589

Reagent substitution in the chromogenic Bethesda assay for factor VIII inhibitors.

Amanda B Payne1, Connie H Miller1, Dorothy Ellingsen1, Jennifer Driggers1, Brian Boylan1, Christopher J Bean1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31359589      PMCID： PMC6827712          DOI： 10.1111/hae.13827

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  10 in total

1.  Definitions in hemophilia: communication from the SSC of the ISTH.

Authors:  V S Blanchette; N S Key; L R Ljung; M J Manco-Johnson; H M van den Berg; A Srivastava
Journal:  J Thromb Haemost       Date:  2014-09-03       Impact factor: 5.824

2.  Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.

Authors:  C H Miller; S J Platt; A S Rice; F Kelly; J M Soucie
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

3.  Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors.

Authors:  C H Miller; A B Payne; J Driggers; D Ellingsen; B Boylan; C J Bean
Journal:  Haemophilia       Date:  2018-03-24       Impact factor: 4.287

4.  The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.

Authors:  B Verbruggen; I Novakova; H Wessels; J Boezeman; M van den Berg; E Mauser-Bunschoten
Journal:  Thromb Haemost       Date:  1995-02       Impact factor: 5.249

Review 5.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

Review 6.  Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Authors:  Peter J Lenting; Cécile V Denis; Olivier D Christophe
Journal:  Blood       Date:  2017-10-17       Impact factor: 22.113

Review 7.  Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B.

Authors:  D M Adcock; K Strandberg; M Shima; R A Marlar
Journal:  Int J Lab Hematol       Date:  2018-07-06       Impact factor: 2.877

8.  Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

Authors:  C H Miller; B Boylan; A D Shapiro; S R Lentz; B M Wicklund
Journal:  J Thromb Haemost       Date:  2017-09-14       Impact factor: 5.824

9.  Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

Authors:  C H Miller; A S Rice; B Boylan; A D Shapiro; S R Lentz; B M Wicklund; F M Kelly; J M Soucie
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

Review 10.  A critical appraisal of one-stage and chromogenic assays of factor VIII activity.

Authors:  F Peyvandi; J Oldenburg; K D Friedman
Journal:  J Thromb Haemost       Date:  2016-02-01       Impact factor: 5.824
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.